



Cosmo Pharmaceuticals' Shareholders approve all Agenda Items at Extraordinary General Meeting

Dublin, Ireland – 16 November 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ("Cosmo") announced that its shareholders approved all agenda items at today's virtual extraordinary general meeting of shareholders.

6,675,344 ordinary shares in the capital of Cosmo were represented at this virtual extraordinary general meeting of shareholders constituting 44.39% of the total issued ordinary shares in the capital of Cosmo (as of the record date).

- The proposal to approve that the Board of Directors of Cosmo enters into the contemplated public exchange offer by Cosmo for all publicly held registered shares in the capital of Cassiopea S.p.A., within the meaning of article 2:107a Dutch Civil Code was adopted by the general meeting of shareholders with 90.11% of the votes cast.
- The proposal to authorise the Board of Directors of Cosmo, for a period of twelve (12) months, to issue - and grant subscription rights to - ordinary shares up to a maximum nominal sum of ten percent (10%) and, in the event of a merger, an acquisition or a strategic alliance to increase this authorisation by a maximum of a further ten percent (10%) of the ordinary shares included in the authorised capital, in addition to the same authorisation granted to the Board of Directors of Cosmo at the annual general meeting of Cosmo on May 28, 2021 was adopted by the general meeting of shareholders with 87.26% of the votes cast.
- The proposal to grant discharge to Eimear Cowhey, a former non-executive member of the Board of Directors of Cosmo in respect of her performed supervision and advice during financial year 2021 up to the day of her resignation was adopted by the general meeting of shareholders with 90.06% of the votes cast.
- The proposal to appoint Alexis de Rosnay as non-executive member of the Board of Directors of Cosmo for a period of one (1) year as of the date of this EGM or the date of the annual general meeting of shareholders in COSMO in 2022 (which ever date comes sooner) was adopted by the general meeting of shareholders with 94.05% of the votes cast.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ its artificial intelligence device that uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk GmbH for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Contact

Niall Donnelly, CFO & Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com